The ESMO Gastrointestinal Cancers Congress 2026 will take place from 1 to 4 July in Munich, Germany, as well as online, through a dedicated virtual platform. Answer who/what/when/where for ESMO Gastrointestinal Cancers Congress 2027 with verified dates, location, and what B2B rea
Presentation data updated Jul 22, 2026, 5:17 AM UTC
This congress is the premier global forum for GI oncology data, focusing on biomarker-driven therapies and early detection across colorectal, pancreatic, and hepatobiliary cancers. Key abstracts will likely shape first-line standard-of-care changes in MSI-H/dMMR and KRAS G12C-mutated tumors. The EU location underscores regulatory focus on HTA and EMA alignment for emerging combos.
Partnerships like Novocure’s tumor-treating fields in pancreatic cancer will highlight device-drug combo adoption. Virtual platform expansion may set a new standard for hybrid access, lowering Phase III trial enrollment costs for community sites.
If biomarker-driven therapies show 3-4 month PFS gains in microsatellite-stable colorectal cancer, this could expand the addressable population beyond current 15% MSI-H. Consensus drug cost forecasts may revise upward by 10-15% for novel GI therapies.
EMA may use real-world evidence presented on liquid biopsy adoption for MRD monitoring to inform future companion diagnostic guidance. Safety signals from novel radio-conjugates could trigger post-market commitments for GI indications.
Catalysts include pivotal data readouts for PD-1/CTLA-4 combos in first-line gastric cancer and new KRAS inhibitors in pancreatic cancer; watch for OS benefits vs standard chemo. De-risking of adverse event profiles for TIGIT bispecifics could move mid-cap biotechs.
Roche’s tiragolumab in gastric cancer and Amgen’s sotorasib in colorectal will face scrutiny against BMS’s Opdivo/Yervoy combo. Daiichi Sankyo’s HER2-DXd data in biliary tract may pressure Pfizer’s trastuzumab biosimilars.
Tier-1 industry catalyst
ESMO Gastrointestinal Cancers Congress is a targeted oncology forum where specialty pipeline readouts and BD conversations drive near-term positioning decisions. Primary driver: speaker calibre and KOL density.
Niche coverage — subscribe for direct abstract alerts.
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
Early science or services-focused — lower near-term PDUFA linkage.
Some historical catalysts; compare readouts against last cycle.
Smaller exhibitor set — focus on disclosed presenters rather than floor traffic.
Nova Pharma Intelligence · Analyst desk
1 presentations tracked — Key Data and Companies hubs live.
Live readouts, late-breakers, and partnership announcements.
Nova editorial monitors confirmed data releases.
Post-event recap, competitive takeaways, and trial updates.
This congress is the premier global forum for GI oncology data, focusing on biomarker-driven therapies and early detection across colorectal, pancreatic, and hepatobiliary cancers. Key abstracts will likely shape first-line standard-of-care changes in MSI-H/dMMR and KRAS G12C-mutated tumors. The EU location underscores
Primary audience: Oncology BD teams · Clinical development leaders · Investors & analysts
Catalysts include pivotal data readouts for PD-1/CTLA-4 combos in first-line gastric cancer and new KRAS inhibitors in pancreatic cancer; watch for OS benefits vs standard chemo. De-risking of adverse event profiles for TIGIT bispecifics could move mid-cap biotechs.
EMA may use real-world evidence presented on liquid biopsy adoption for MRD monitoring to inform future companion diagnostic guidance. Safety signals from novel radio-conjugates could trigger post-market commitments for GI indications.
Roche’s tiragolumab in gastric cancer and Amgen’s sotorasib in colorectal will face scrutiny against BMS’s Opdivo/Yervoy combo. Daiichi Sankyo’s HER2-DXd data in biliary tract may pressure Pfizer’s trastuzumab biosimilars.
| Edition | Presentations | Companies |
|---|---|---|
| ESMO Gastrointestinal Cancers Congress (current) | 1 | 1 |
| ESMO Preceptorship on Neuroendocrine (2026) | 0 | 0 |
| ESMO (2026) | 0 | 0 |
Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC
Roche’s tiragolumab in gastric cancer and Amgen’s sotorasib in colorectal will face scrutiny against BMS’s Opdivo/Yervoy combo. Daiichi Sankyo’s HER2-DXd data in biliary tract may pressure Pfizer’s trastuzumab biosimilars.
No coverage articles yet. Check back closer to the event.
Standalone summaries for ESMO Gastrointestinal Cancers Congress — optimized for research and AI retrieval.
This congress is the premier global forum for GI oncology data, focusing on biomarker-driven therapies and early detection across colorectal, pancreatic, and hepatobiliary cancers. Key abstracts will likely shape first-line standard-of-care changes in MSI-H/dMMR and KRAS G12C-mutated tumors. The EU location underscores
Focus on KRAS G12C inhibitor data in colorectal as a potential comparable to Amgen's Lumakras; any win in pancreatic would be a sector disrupter. Also track HER2-targeted ADCs in gastric and biliary as these are high-volume value drivers for 2027 revenue forecasts.
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ESMO Gastrointestinal Cancers Congress.
BD teams should prioritize networking with presenting companies and services vendors at ESMO Gastrointestinal Cancers Congress, focusing on oncology partnership and licensing opportunities.
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
ESMO Gastrointestinal Cancers Congress is a oncology industry conference bringing together executives, clinical leaders, and investors to discuss pipeline, regulatory, and commercial strategy.
Typical attendees include pharma executives, BD teams, investors, regulatory affairs professionals, and clinical operations leaders focused on oncology.
ESMO Gastrointestinal Cancers Congress influences partnership timing, pipeline prioritization, and policy debates that affect oncology markets for the next 12–18 months.
ESMO Gastrointestinal Cancers Congress takes place on the scheduled dates.
ESMO Gastrointestinal Cancers Congress is held in the listed venue.
1+ companies present data or participate in programming at ESMO Gastrointestinal Cancers Congress, spanning large pharma, biotech, and services vendors.
Investors should track partnership announcements, pipeline readouts, M&A signals, and management commentary on oncology catalysts during and after ESMO Gastrointestinal Cancers Congress.
BD teams use ESMO Gastrointestinal Cancers Congress for licensing discussions, co-development talks, and vendor selection across oncology — especially in networking sessions and satellite meetings.
ESMO Gastrointestinal Cancers Congress is a tier-1 global congress for oncology — compare speaker quality, company participation, and historical deal flow with peer events in the same therapeutic or commercial vertical.
NovaPharmaNews publishes pre-event briefs, live coverage, and post-event analysis for ESMO Gastrointestinal Cancers Congress. Subscribe to event alerts on this page for breaking updates.